A study comparing baseline demographic , clinical characteristics and assessing outcomes of ibrutinib-treated patients with and without del(17p)
Latest Information Update: 04 Jan 2021
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 04 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology